Cargando…

Androgen deprivation and SARS-CoV-2 in men with prostate cancer

Detalles Bibliográficos
Autores principales:	Koskinen, M., Carpen, O., Honkanen, V., Seppänen, M.R.J., Miettinen, P.J., Tuominen, J.A., Raivio, T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Ltd on behalf of European Society for Medical Oncology. 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323668/ https://www.ncbi.nlm.nih.gov/pubmed/32615154 http://dx.doi.org/10.1016/j.annonc.2020.06.015

Ejemplares similares

Androgen-deprivation therapy and SARS-CoV-2 in men with prostate cancer: findings from the University of California Health System registry
por: Kwon, D.H., et al.
Publicado: (2021)

On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2
por: Caffo, O., et al.
Publicado: (2020)

Prostate cancer, insulin, and androgen deprivation therapy
por: Stattin, P, et al.
Publicado: (2003)

Reply: Prostate cancer, insulin and androgen deprivation therapy
por: Lehrer, S
Publicado: (2003)

Androgen deprivation therapy in high risk prostate cancer
por: Van Dams, Ritchell, et al.
Publicado: (2019)

Androgen-deprivation therapy and SARS-Cov-2 infection: the potential double-face role of testosterone
por: Salciccia, Stefano, et al.
Publicado: (2020)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer
por: Shah, Neil J, et al.
Publicado: (2022)

Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer
por: Morrison, Belinda F, et al.
Publicado: (2011)

Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With Prostate Cancer
por: Gagliano-Jucá, Thiago, et al.
Publicado: (2018)

Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate Cancer
por: Jayadevappa, Ravishankar, et al.
Publicado: (2019)

Review of Cardiovascular Risk of Androgen Deprivation Therapy and the Influence of Race in Men with Prostate Cancer
por: Fradin, James, et al.
Publicado: (2023)

Androgen Deprivation Therapy, Hypogonadism and Cardiovascular Toxicity in Men with Advanced Prostate Cancer
por: Gheorghe, Gabriela Silvia, et al.
Publicado: (2021)

Association between Androgen Deprivation Therapy and Risk of Dementia in Men with Prostate Cancer
por: Liu, Jui-Ming, et al.
Publicado: (2021)

Changes in cerebral metabolic activity in men undergoing androgen deprivation therapy for non-metastatic prostate cancer
por: Cherrier, M. M., et al.
Publicado: (2018)

The clinical relevance of adiposity when assessing muscle health in men treated with androgen deprivation for prostate cancer
por: Owen, Patrick J., et al.
Publicado: (2019)

Survival following primary androgen deprivation therapy among men with localized prostate cancer
por: Vasudeva, Pawan, et al.
Publicado: (2008)

A pilot study of exercise in men with prostate cancer receiving androgen deprivation therapy
por: Lee, C Ellen, et al.
Publicado: (2012)

Androgen Deprivation Therapy Reversibly Increases Endothelium‐Dependent Vasodilation in Men With Prostate Cancer
por: Nguyen, Paul L., et al.
Publicado: (2015)

Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer
por: Shore, Richard, et al.
Publicado: (2021)

Two Elderly Men with Myasthenia Gravis during Androgen Deprivation Therapy for Prostate Cancer
por: Kanazawa, Kazo, et al.
Publicado: (2023)

Reversing the effects of androgen-deprivation therapy in men with metastatic castration-resistant prostate cancer
por: Marshall, Catherine H., et al.
Publicado: (2021)

Predictors of Fracture Risk and Bone Mineral Density in Men with Prostate Cancer on Androgen Deprivation Therapy
por: Neubecker, Katherine, et al.
Publicado: (2011)

Effect of androgen deprivation therapy on cognitive functioning in men with prostate cancer: A systematic review
por: Andela, Cornelie D, et al.
Publicado: (2021)

Effects of a lifestyle intervention on endothelial function in men on long-term androgen deprivation therapy for prostate cancer
por: Gilbert, Stephen E, et al.
Publicado: (2016)

Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
por: Chen, Mengqian, et al.
Publicado: (2010)

Impacts of androgen deprivation therapy on the risks and outcomes of SARS-CoV-2 infection in patients with prostate cancer
por: Huang, Yuan-Bin, et al.
Publicado: (2022)

The Use of Androgen Deprivation Therapy (ADT) and Chemotherapeutic Agents in New Zealand Men with Prostate Cancer
por: Lawrenson, Ross, et al.
Publicado: (2014)

Cardiometabolic and Skeletal Risk Factors in Black Men with Prostate Cancer Starting Androgen Deprivation Therapy
por: Gunnarsson, Orvar, et al.
Publicado: (2015)

Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer
por: Crawley, Danielle, et al.
Publicado: (2016)

Retrospective cohort study of androgen deprivation therapy and the risk of diabetes in men with prostate cancer in Lithuania
por: Drevinskaite, Mingaile, et al.
Publicado: (2021)

Androgen deprivation therapy and risk of cognitive dysfunction in men with prostate cancer: is there a possible link?
por: Shim, Myungsun, et al.
Publicado: (2022)

NRG1 Genetic Variant Influences the Efficacy of Androgen-Deprivation Therapy in Men with Prostate Cancer
por: Huang, Shu-Pin, et al.
Publicado: (2021)

A Novel Liver-targeted Testosterone Therapy for Sarcopenia in Androgen Deprived Men With Prostate Cancer
por: Rhee, Handoo, et al.
Publicado: (2021)

Corrigendum to “Predictors of Fracture Risk and Bone Mineral Density in Men with Prostate Cancer on Androgen Deprivation Therapy”
por: Neubecker, Katherine, et al.
Publicado: (2017)

The effectiveness of lifestyle interventions to reduce side effects of androgen deprivation therapy for men with prostate cancer: a systematic review
por: Geerkens, Maud J. M., et al.
Publicado: (2019)

Reporting and ideal testosterone levels in men undergoing androgen deprivation for prostate cancer—time for a rethink?
por: Cabarkapa, Sonja, et al.
Publicado: (2018)

Androgen Deprivation Therapy Differentially Impacts Bone and Muscle in the Short Term in Physically Active Men With Prostate Cancer
por: Maalouf, Naim M., et al.
Publicado: (2021)

Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation Therapy
por: Graff, Julie N., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vej1kcbje6k57djlpabue198oh